



This is a repository copy of *Non-responsive coeliac disease : a comprehensive review from the NHS England national centre for refractory coeliac disease*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/156944/>

Version: Published Version

---

**Article:**

Penny, H.A. [orcid.org/0000-0003-1610-2282](https://orcid.org/0000-0003-1610-2282), Baggus, E.M.R., Rej, A. et al. (2 more authors) (2020) Non-responsive coeliac disease : a comprehensive review from the NHS England national centre for refractory coeliac disease. *Nutrients*, 12 (1). 216.

<https://doi.org/10.3390/nu12010216>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:  
<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

Review

# Non-Responsive Coeliac Disease: A Comprehensive Review from the NHS England National Centre for Refractory Coeliac Disease

Hugo A. Penny<sup>1,2</sup>, Elisabeth M. R. Baggus<sup>1</sup> , Anupam Rej<sup>1</sup> , John A. Snowden<sup>3</sup>   
and David S. Sanders<sup>1,\*</sup>

<sup>1</sup> Academic Unit of Gastroenterology, University of Sheffield, Sheffield S10 2TN, UK; h.penny@sheffield.ac.uk (H.A.P.); emrbaggus1@sheffield.ac.uk (E.M.R.B.); anupam.rej@nhs.net (A.R.)

<sup>2</sup> Lydia Becker Institute of Inflammation and Immunology, University of Manchester, Manchester M13 9PL, UK

<sup>3</sup> Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S10 2JF, UK; john.snowden1@nhs.net

\* Correspondence: david.sanders1@nhs.net; Tel.: +44-114-226-1179

Received: 19 December 2019; Accepted: 9 January 2020; Published: 14 January 2020



**Abstract:** Coeliac disease is a common small intestinal enteropathy which manifests following ingestion of gluten in genetically susceptible individuals. Since gluten was identified as the driving factor in coeliac disease, the gluten-free diet (GFD) has remained the mainstay of treatment. While most individuals will display improvement in symptoms and signs of coeliac disease following institution of the GFD, up to 30% will continue to experience symptoms and/or have persisting intestinal inflammation. These individuals can be classified as having non-responsive coeliac disease (NRCD), which may be associated with dietary indiscretion, slow healing, refractory coeliac disease, and/or an alternative condition. The purpose of this review is to provide an overview of the causes of NRCD in adults, highlight a systematic approach to investigate these patients, and appraise the latest management aspects of this subset of coeliac disease.

**Keywords:** coeliac disease; non-responsiveness; refractory coeliac disease; gluten free diet

## 1. Introduction

Coeliac disease (CD) is a chronic, autoimmune condition that develops in genetically susceptible individuals and has a reported prevalence of around 1% [1]. While the disease is characterized by a small intestinal enteropathy, the manifestations are broad and can involve both the gastrointestinal intestinal tract and distinct extra-intestinal sites throughout the body [2]. Inflammation and tissue damage in the small intestine results from an abnormal immune response towards ingested gluten. Persisting inflammation in active CD puts individuals at risk of osteoporosis, nutrient deficiencies, and malignancies [2]. Thus, a life-long gluten-free diet (GFD) is the mainstay treatment and reduces the long-term complications of this condition [2]. While most individuals will display improvement in symptoms and signs of CD following institution of the GFD, up to 30% will continue to experience symptoms and/or have persisting intestinal inflammation [3]. These individuals are classified as having non-responsive CD (NRCD), which may be associated with dietary indiscretion, slow healing, refractory CD (RCD), and/or an alternative diagnosis to CD [3].

In this article, we provide a comprehensive overview of the causes of NRCD in adults and highlight a systematic approach to investigate these patients. Furthermore, we appraise the latest management aspects of NRCD, with a particular focus on RCD. In doing so, it is hoped that this article

will help promote the correct and timely identification, multi-disciplinary appraisal, and treatment of individuals with NRCD, in order to reduce morbidity and mortality associated with this subset of CD.

## 2. Defining Non-Responsive Coeliac Disease

It is generally accepted that NRCD is defined as persistent symptoms, signs, laboratory abnormalities, or histological changes typical of CD, despite at least 6 to 12 months of presumed adherence to a GFD [4]. Whilst this time length is often quoted in the definition of NRCD, it is arbitrary, as the length of time needed to respond to a GFD is variable and thus it is important to be guided by the clinical picture [5]. NRCD can be categorized as primary, where there is no response to a GFD, or secondary, where individuals initially respond to a GFD, but then develop symptoms despite ongoing adherence to a GFD [3]. Some expert gastroenterologists have suggested that the definition of NRCD causes confusion, primarily because the underlying cause of symptoms in these individuals may be related, or unrelated, to CD [6]. In contrast, we consider this definition appropriate, as it puts CD at the forefront of the clinical approach when considering the causes of persisting symptoms in these patients.

## 3. Causes of Non-Responsive Coeliac Disease

### 3.1. An Alternative Primary Diagnosis

An obvious but crucial first step in considering the cause of NRCD is to re-examine the primary diagnosis of CD. This is particularly important in the setting of a patient with a historical diagnosis of CD presenting with secondary non-responsiveness, because diagnostic testing in CD has advanced greatly over the last two decades, alongside a shift in our understanding of how CD manifests in adults, with a greater emphasis on extra-intestinal signs and symptoms than previously thought [2]. Indeed, case series suggest that around 8% of patients evaluated with a presumed diagnosis of NRCD did not have an original diagnosis of CD [7,8].

Confirming the diagnosis of CD is achieved by reviewing serology and histology taken at the time of diagnosis. Notably, the detection of circulating anti-gliadin antibodies (AGA) was heavily relied upon in the serological diagnosis of CD up until around the early 2000s [9]. However, it has since been demonstrated that the AGA test has poor sensitivity and specificity for CD, and this assay has now been superseded by those that detect anti-tissue transglutaminase (TTG) and -endomysial (EMA) antibodies, which have greater disease specificity [10]. In addition, selective immunoglobulin (Ig) A deficiency is 10-fold more common in patients with coeliac disease than the general population (2% vs. 0.2%, respectively) [11]. Most first-line TTG and EMA assays detect IgA antibodies. In view of this, IgA deficiency is important to test for, and, if present, IgG-based serological testing should be undertaken [12].

It is also of note that the recent past has seen the recognition of a broader group of disorders that fall under the spectrum of CD, which include 'potential' and 'seronegative' CD [2]. Whilst villous atrophy in the context of negative serology maybe due to CD, other diagnoses must be considered first, as CD only accounts for 30% of serology negative villous atrophy [13]. Other causes include immune-mediated (e.g., autoimmune enteropathy), inflammatory (e.g., eosinophilic gastroenteritis), infectious (e.g., giardiasis), iatrogenic (e.g., NSAIDs), and idiopathic causes [14]. Finally, variability exists in the identification of the main histological changes of CD, which can lead to diagnostic uncertainty [15,16].

Therefore, if re-examining the primary diagnosis raises any doubt, up to date coeliac serology and duodenal biopsies should be performed. It is noteworthy that these individuals are likely excluding gluten from their diet, so biopsies should be performed following a gluten challenge—at least 6 weeks of 10g of gluten/day [12]. In addition, human leucocyte antigen (HLA) typing can be used as a negative predictive test to exclude CD, as positive HLA typing occurs in up to 99.7% of individuals with CD [17].

However, HLA typing cannot be used to solely diagnose CD, as it is present in up to 40% of the general population [18].

### 3.2. An Associated Condition

Coeliac disease is associated with a number of conditions, including microscopic colitis, pancreatic insufficiency, small intestinal bacterial overgrowth (SIBO), inflammatory bowel disease (IBD), and lactose or fructose intolerance (Table 1) [5,19–22]. These are either related (SIBO, lactose/fructose intolerance) or unrelated (IBD, microscopic colitis) to mucosal damage in CD and can co-present at the time of index CD diagnosis or manifest after diagnosis. Therefore, the presence of these conditions should be considered as a cause for persisting symptoms in coeliac patients and managed accordingly.

**Table 1.** Conditions associated with coeliac disease that should be considered as a cause for persisting symptoms in coeliac patients [5,19–22].

Pancreatic insufficiency
Inflammatory bowel disease
Lactose and/or fructose intolerance
Small intestinal bacterial overgrowth
Microscopic colitis
Irritable bowel syndrome
Functional dysmotility

In addition, functional gastrointestinal disorders, such as irritable bowel syndrome (IBS) and gastrointestinal dysmotility, are more prevalent in individuals with CD [23,24] and should not be overlooked as a cause of persisting symptoms in individuals with normal repeat duodenal histology. For these individuals, a low fermentable oligo-, di-, mono-saccharide and polyol (FODMAP) diet may improve symptoms and quality of life [25,26]. In one study, 41 CD patients with IBS who had been on a GFD for at least 1 year demonstrated significant improvement in IBS-symptom severity scores after 3 months on the low FODMAP diet [25]. The benefits of a low FODMAP diet have also been shown in a recent randomized controlled trial; 50 patients with CD and persisting symptoms were randomized to follow either a regular GFD (R-GFD,  $n = 25$ ) or a low FODMAP GFD (LF-GFD,  $n = 25$ ) for 21 days. At the end of the 21 days, symptoms were reduced in the LF-GFD group, but not in the R-GFD group. General wellbeing increased in both groups, but a significantly higher improvement was noted in the LF-GFD group [26]. This suggests an additive effect of combining a low FODMAP diet with a GFD in certain individuals with NRCD. However, notably, these studies did not rule-out persistent villous atrophy as a cause for ongoing symptoms.

In addition to the low FODMAP diet, probiotics have shown potential benefits in individuals with CD and IBS symptoms. A recent randomized, double-blind, placebo-controlled multicenter trial investigated the use of a probiotic mixture in patients with CD with persisting IBS-type symptoms despite a strict GFD [27]. In total, 109 CD patients were randomized to receive either probiotics or a placebo for 6 weeks. The investigators noted a significantly greater reduction in symptoms with the use of probiotics compared with the placebo [27]. However, while these results are promising, further studies are needed to evaluate the use of the low FODMAP diet and/or probiotics in NRCD associated with functional gastrointestinal disorders.

### 3.3. Dietary Indiscretion

Ongoing gluten ingestion (either deliberate or inadvertent) is reported in around 35–50% of cases of NRCD and thus is one of the commonest causes of persistent CD [7,8]. While it has been estimated that effective adherence to a GFD occurs in only 40–90% of cases, complete non-adherence is uncommon, with most studies reporting it in less than 5% of individuals [5,28]. This underscores the difficulty in maintaining a strict GFD. Indeed, inadvertent exposure may even occur in the setting of

presumed gluten abstinence, as highlighted in a recent study which reported that gluten was detected by a commercially available home testing kit in 32% of gluten-free labelled restaurant food [29].

Assessing adherence to a GFD is notoriously difficult. A detailed dietary history including the use of food diaries is an effective and commonly used method and can identify inadvertent gluten exposure, particularly if individuals lack an understanding of which foodstuffs/products contain gluten. However, as mentioned, gluten exposure can occur in the setting of presumed abstinence and thus would not be identified by this method. As gluten exposure causes on-going symptoms in patients with CD, detailed symptom assessment at follow-up is important to determine. However, gluten exposure may not lead to symptoms in all patients, and around 20% of individuals with CD are asymptomatic at diagnosis [30]. Serological markers (anti-TTG and -EMA antibodies) have traditionally been used in clinical practice to monitor for adherence. The normalization of circulating TTG titers after institution of a GFD is often (mis-)taken to reflect a reduction in inflammation and mucosal healing, which itself is considered evidence of effective adherence to a GFD. However, a recent meta-analysis interrogating the diagnostic accuracy of elevated anti-TTG and -EMA IgA antibodies for predicting persistent villous atrophy in individuals on a GFD demonstrated a specificity of 0.83 (95% confidence interval [CI] 0.79–0.87) and 0.91 (95% CI 0.87–0.94) and a sensitivity of 0.5 (95% CI 0.41–0.60) and 0.45 (95% CI 0.34–0.57), respectively [31]. Therefore, these serological tests cannot be relied upon to inform on mucosal healing after the institution of a GFD.

In view of this, repeat duodenal biopsy is currently the best way to assess for mucosal healing and thus, indirectly inform on effective gluten abstinence [4]. However, it is difficult to predict the most appropriate time to perform repeat duodenal biopsies in CD, because the rate of mucosal recovery following the institution of a GFD varies between individuals. Some studies suggest that histological remission occurs in most individuals (68%) within the first year following diagnosis [32]. However, other observational studies have reported histological remission in 34–65% of individuals up to two years post-diagnosis, and others have suggested that mucosal recovery may even take as long as 5 years in some individuals [33–36]. It is therefore important to be aware that some patients with CD may be ‘slow responders’ to the GFD and, as such, persisting villous atrophy on follow-up biopsies may not reflect true dietary indiscretion.

The use of faecal and urine gluten immunogenic peptides (GIPs) may provide a practical non-invasive future approach to monitor for gluten exposure in individuals. In a recent study, patients with CD who reported adherence to a strict GFD had a positive GIP, despite the majority of these individuals being asymptomatic [37]. This highlights the potential utility of using GIPs in assessing ongoing gluten exposure. However, so far, these tests have failed to gain widespread acceptance into clinical practice owing to certain limitations. Namely, urine and faecal GIPs are only able to detect gluten ingestion 1–2 days and 2–4 days, prior to testing, respectively [38]. Therefore, it is possible that the window of gluten exposure is missed by the time individuals are tested for GIPs. Notably, this is not the only non-invasive marker of gluten exposure available, and the last decade has seen a rise in the development of other commercially available tests, including point of care tests [39]. However, robustly designed studies are awaited to assess their place in clinical practice.

#### 3.4. *Gluten Super-Sensitivity*

In the UK, foods that contain 20 parts per million or less gluten can be branded as gluten free. It is generally considered that the vast majority of individuals with CD will tolerate foodstuffs with gluten at this level [5]. However, some individuals are sensitive to small traces of gluten (less than 20 parts per million) and thus display an incomplete response to a strict GFD [40].

The Gluten Contamination Elimination Diet (GCED) comprises whole, unprocessed foods and has been developed to prevent ingestion of trace amounts of gluten [40]. This has been shown to result in an improvement in symptoms in this (super-sensitive) subset of individuals with NRCD who are adherent to a GFD [40]. It is thought that the GCED may also be used to distinguish between individuals who are ‘supersensitive’ to a GFD and those with true RCD [41]. This could be particularly

useful in preventing patients receiving unnecessary corticosteroid and immunosuppressive treatment for an incorrect diagnosis of RCD [4]. Notably, other diets exclusive of trace gluten have also been trialed in this setting, including the elemental diet. This has demonstrated potential benefits, with both histological and clinical improvement being demonstrated in small case series [42,43]. However, there is a lack of large, long-term studies assessing the efficacy and acceptability of either diets in this patient cohort.

### 3.5. Refractory Coeliac Disease

#### 3.5.1. Overview

RCD is defined as persistent or recurrent malabsorptive symptoms/signs with villous atrophy, despite adherence to a strict GFD for at least 12 months [44]. However, RCD may be suspected before this as patients with RCD often show little response to a GFD, meaning these patients may present with severe and/or progressive symptoms before this 12-month GFD trial period [4].


RCD has a reported prevalence of 0.3–4% of patients with CD [45–48] and is reported to account for 8–23% of NRCD cases [7,8,47]. This wide prevalence range likely reflects the difficulty in differentiating between inadvertent gluten exposure, slow responders, individuals with super-sensitivity and true RCD. As a result, RCD may be over-diagnosed and the true prevalence in this cohort is likely to be lower than that reported.

Individuals with RCD can be sub-classified as having either RCD Type 1 (RCD1) or Type 2 (RCD2), based on the abnormal expansion of a subset of small intestinal intraepithelial lymphocytes (IELs), which occurs in RCD2 [49]. RCD2 is predominantly diagnosed in adults aged 50 or above, although younger cases have been observed [48]. Patients with RCD2 are more likely to present with constitutional symptoms, such as weight loss and nutrient deficiencies, than those with RCD1, which reflects prolonged severe mucosal inflammation in these patients [46]. The presence of other symptoms, such as gastrointestinal bleeding, fever, night sweats, and bowel obstruction, should lead to the consideration of complications associated with RCD, such as enteropathy associated T-cell lymphoma (EATL) and ulcerative jejunitis (UJ) [50]. The latter, in particular, is common in patients with RCD2 and is characterized by areas of multiple chronic ulcers with a benign appearance [46].

Patients with RCD1 often show good response to treatment and the 5-year survival is 80–100% [45,46]. In contrast, treatment options are limited in RCD2 and the 5-year prognosis is around 50% [45–47,51,52]. Mortality in RCD2 may occur either as a result of malabsorption and consequent malnutrition, or from the development of associated complications, including EATL [45,46]. Progression to EATL is reported to occur in 33–67% of RCD2 cases; EATL itself has a 5-year survival of only around 10% [45,46,51,52].

#### 3.5.2. Diagnosis

Persisting/worsening symptoms and villous atrophy despite strict adherence to a GFD should prompt the clinician to consider a diagnosis of RCD. A flow chart outlining the stepwise investigation of these patients is shown in Figure 1. Once RCD is suspected, detailed evaluation of up-to-date duodenal biopsies should be performed. This is beyond the scope of histological assessment of duodenal biopsies for CD diagnosis and should be undertaken at specialist centers that are experienced in the diagnosis of RCD.



**Figure 1.** Algorithm for investigating coeliac patients with persisting symptoms. Investigations outlined in the green box can be planned for during the initial follow-up appointment in suspected non-responsive coeliac disease (NRCD). This may expedite the identification and diagnosis of RCD. Where there is clear clinical concern of ongoing gluten ingestion, a dietary review earlier in the investigation pathway may prevent unnecessary tests for some patients. However, we would always advocate repeat duodenal biopsies in individuals presenting with NRCD. Modified with permission from [4].

Individuals with RCD2 demonstrate an abnormal expansion of a subset of small intestinal IELs [49]. These IELs are often described as being ‘aberrant’, as they lack the usual expression of cell surface proteins, such as CD3 and CD8, but do express intracellular CD3 [53,54]. It is important to note that this IEL subset is present in normal individuals, uncomplicated CD, and RCD1, but at lower frequencies to that is found in RCD2 [53,54]. In RCD2, there is evidence that aberrant IELs display clonal rearrangement of their T cell receptor (TCR) [53–55]. However, clonal rearrangement of the TCR is not unique to RCD2 and has been described transiently in uncomplicated CD at the time of diagnosis and in individuals with CD who continue to ingest gluten [56,57]. TCR clonality alone is therefore not an adequate indicator of RCD2, which requires quantification of the frequency of the aberrant IEL subset within the small intestine [58].

The frequency of aberrant IELs within the small intestine can be determined by either flow cytometry or immunohistochemistry (IHC). Flow cytometry is a highly specialized laser-based technique which can measure morphometric and phenotypic characteristics of individual cells simultaneously [59]. IHC is a widely available microscopy-based technique that enables visualization

of cellular components by the operator. Using flow cytometry, RCD2 is diagnosed when the frequency of aberrant IELs exceeds 20% of the isolated lymphocyte pool [58]. By IHC, the threshold frequency of aberrant IELs required for a diagnosis of RCD2 is raised to >40% [58]. This is because flow cytometry is considered a more accurate method to enumerate the frequency of aberrant IELs than IHC and therefore is currently the preferred approach in RCD [60]. However, flow cytometry is subject to laborious sample preparation and variable cell yields from tissue preparations [59,60]. Furthermore, flow cytometry is not widely available, with its use being restricted to specialized centers, and further validation is necessary before wider testing can be provided. This could lead to delays in diagnosis and initiation of treatment of patients with RCD2. Notably, the cell surface receptor, NKp46, is detected on aberrant IELs [54]. Cheminant et al. [61] recently reported that the presence of >25 NKp46+ IELs/100 epithelial cells accurately discriminated RCD2 from CD and RCD1. In this study, NKp46 expression was detected by IHC staining of duodenal biopsy sections [61]. Therefore, this approach may represent an accurate, yet more widely available, alternative to flow cytometry for risk stratification/identification of individuals with suspected RCD2.

The requirement for multiple diagnostic modalities in the evolving methodology of diagnosing RCD supports the diagnosis of RCD within integrated haemato-pathology systems [62]. Currently, such specialized testing is limited to specialist centers with an interest in RCD, and further research is warranted to validate diagnostic methodology, classification criteria, and prognostic systems, as well as developing novel biomarkers before diagnostics in RCD can be delivered in a more widely available and quality assured manner.

### 3.5.3. Management

#### (i) General Measures

Management of RCD is challenging, and patients should be referred to a tertiary center with experience in RCD for treatment. Treatment widely depends on the type of RCD, but general measures include nutritional support and managing the complications associated with prolonged malabsorption and malnutrition [4]. Routine investigations, including haematinics, iron studies, electrolytes, albumin, magnesium, and calcium, should be checked and replaced where necessary [4]. In individuals presenting with severe malabsorption and weight loss, trace elements, including zinc and copper, should also be checked and corrected [4]. Consideration should be taken to monitor for re-feeding syndrome alongside early nutritional support.

#### (ii) RCD1

The aim of management of RCD1 is to improve symptoms and promote histological recovery. Follow-up is important to assess for progression to RCD2 and/or malignancy. In a subset of patients, maintenance of a strict GFD alongside nutritional support has been demonstrated to induce symptomatic and histological improvement [45,46]. However, the mainstay of therapy is nutritional support and corticosteroids +/- azathioprine, and most patients with RCD1 achieve clinical remission and mucosal healing with this approach [50,63].

Individuals with RCD1 should be started on oral steroids (prednisolone, 0.5–1 mg/kg/day) alongside agents to prevent loss of bone mineral density [4]. The majority of patients with RCD1 will be steroid dependent [45,64]. In view of this, budesonide (9 mg/day) has been used as an alternative to prednisolone therapy, with the intention of reducing the risks associated with systemic oral steroid therapy [4]. Modified release budesonide has a systemic bioavailability of 12% [65], although it is thought that availability may be increased in those with mucosal disease. Therefore, there is the possibility that patients taking budesonide may be exposed to similar long-term risks as with oral prednisolone therapy [60]. When considering any preparation of budesonide (Entocort or Budenofalk), it is important to note that these are only bioavailable in the small bowel if the tablet is ground down or the capsule is opened [4]. Therefore, patients should be asked to grind the medication with their teeth prior to ingestion in order to optimize small bowel efficacy [66].

After induction of clinical remission, azathioprine can be added (2–2.5 mg/kg/day) [4]. Combination therapy, using azathioprine and prednisolone, may be superior to steroids alone, although normalization of villi is seen in only around half of patients [45,67] and there is a lack of adequately controlled studies comparing mono- or combination therapy in RCD1. There have been concerns that the use of azathioprine may increase the risk for development of lymphoma. However, a study in 43 RCD1 patients failed to demonstrate this over a follow-up period of 72 months [51].

Azathioprine is metabolized by the body into the pharmacologically active metabolite, thioguanine nucleotide (TGN) [68]. In individuals who fail to respond to azathioprine, TGN levels should be measured to ensure adequate drug metabolism and to enable dosage optimization [60]. A thiopurine derivative, thioguanine, has been used in a small cohort ( $n = 12$ ) of individuals with RCD1 and demonstrated histological improvement in around 2/3rds of individuals, as well as reduced steroid dependency [68]. Infliximab may be a therapeutic option for individuals who fail to respond to azathioprine therapy; however, the evidence for its potential efficacy has only been described in case reports to date [69,70]. The benefit of small intestinal release mesalamine (SIRM) in RCD1 patients as a steroid-sparing agent has also been reported in a recent small study, although there is a lack of other data supporting these findings [71].

In individuals with RCD1, a follow-up intestinal biopsy after 3 months of treatment should be performed to assess for histological response [4]. Once treatment response has been established, it is recommended that repeat duodenal biopsies are performed annually to monitor for expansion of the aberrant IEL subset, which would suggest progression to RCD2 [4]. The withdrawal of azathioprine after 2–3 years of complete response should be considered in order to confirm the diagnosis of RCD1 rather than a slow response to gluten withdrawal [60].

### (iii) RCD2

Once RCD2 is diagnosed, individuals should be assessed for EATL. Investigations to be considered should include cross-sectional imaging such as an abdominal CT scan, MR enteroclysis, a fluorodeoxyglucose-positron emission tomography scan, enteroscopy, and capsule endoscopy [72–78]. Following this, the management of RCD2 is aimed at symptom improvement and reducing the risk of progression to EATL. Since RCD2 is rare, the evidence base for its management is limited to a number of case series, and, notably, there is no evidence that EATL can be prevented, although treatment may delay its onset [4].

It is recommended that treatment for RCD2 is initiated with prednisolone or budesonide [4]. In one study, 77% of RCD2 patients treated with corticosteroids ( $n = 30$ ) had a clinical response (defined as 50% reduction in symptoms and/or 50% regain of lost weight prior to treatment) and 33% showed histological improvement (7 partial improvement and 3 complete mucosal healing) with systemic corticosteroids [46]. Budesonide has also been used with some success in RCD2. In one study, 7/13 RCD2 patients treated with open-capsule budesonide showed a reduction in the frequency of aberrant IELs on follow-up biopsies [66] and other studies support the use of budesonide in RCD2 [64].

Unlike in RCD1, azathioprine is not recommended as a therapy in RCD2 due to concerns regarding lymphomagenesis with thiopurine treatment and the increased risk of EATL development in these individuals [67]. This is despite early studies showing encouraging subjective clinical and histological responses in RCD2 [67,71]. The use of the adenosine nucleoside analogue cladribine has been documented in patients with RCD2. One study of 32 patients reported clinical, histological, and immunological improvement in 81%, 47%, and 41% of patients, respectively, with progression into EATL reported in 16% of individuals [79]. Another study of 17 patients demonstrated clinical and histological improvement, and a significant decrease in the frequency of aberrant IELs in 36%, 59%, and 35% of patients, respectively [80]. However, despite mucosal recovery and a reduction in the proportion of aberrant IELs, all patients still fell within the classification for RCD2, and 41% of this group developed EATL [80]. Therefore, treatment with cladribine in RCD2 has been shown to be well

tolerated and can induce clinical and histologic improvement in some patients, although it does not prevent EATL development [4].

There are a number of other immunosuppressive medications which have been trialed in small case series/ reports in RCD2, including infliximab [68,69,81], campath (anti-CD52) [46,82], methotrexate [46], ciclosporin [46,83], and recombinant interleukin (IL)-10 [84]. Recently, anti-IL-15 monoclonal antibody treatment was used in a randomized double-blind placebo-controlled study. In patients with RCD2 who were treated with an IL-15 monoclonal antibody or placebo for 10 weeks, there was no difference in the primary endpoint of reduction of aberrant IEL frequency from baseline between groups [85]. However, an improvement in symptoms was noted, and anti-IL-15 is potentially available as part of a compassionate-use programme in RCD2 [4].

Immunoablative chemotherapy, followed by autologous haemopoietic stem cell transplantation (aHSCT), now indicated in a range of autoimmune and inflammatory diseases [86–88], has been used rarely to treat RCD2, mainly in a single center, with limited evidence that it may prevent progression to EATL. Results of a step-up program, incorporating the use of aHSCT in patients who do not achieve histological responses to cladribine, have been published [89–91]. Further observational and prospective studies with greater numbers are warranted to define the risk:benefit ratio of aHSCT (and its intrinsic toxicities) and where it should feature in the treatment algorithm for RCD2. Until then, current recommendations are that aHSCT can be considered as an option for individual patients after careful discussions of risks and benefits and can be performed in accredited specialist centers with major experience and appropriate infrastructure [88].

A case report has also documented the potential benefit of faecal microbial transplant in RCD2 [92]. A patient with RCD2 who received a faecal microbial transplant for recurrent *Clostridium difficile* infection subsequently showed full mucosal recovery and disappearance of coeliac symptoms. Dysbiosis has been demonstrated in both CD and RCD [93–100], and collectively these studies suggest that targeting the intestinal microbiota may provide future therapeutic strategies for the treatment of RCD, although it is first necessary to understand clearly the pathological mechanisms underlying dysbiosis and CD/RCD.

#### 4. Conclusions

Up to a third of individuals with CD develop NRCD. Dietary indiscretion is the commonest cause of NRCD, yet currently there is no reliable objective assessment of ongoing gluten ingestion in these patients. The diagnosis and management of RCD is challenging, and patients should be referred to a specialist center with multi-disciplinary experience in RCD for assessment, diagnostics, treatment, and follow-up. Novel therapeutic strategies are required to provide realistic treatment options in RCD2 to impact the dismal mortality in this condition.

**Author Contributions:** H.A.P., E.M.R.B., A.R., J.A.S., and D.S.S. wrote the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding

**Acknowledgments:** No funding was obtained for this review. H.A.P. is a Wellcome Clinical Fellow funded on grant 203914/Z/16/Z to the Universities of Manchester, Leeds, Newcastle, and Sheffield. D.S.S. receives an educational grant from Dr Schär (a gluten-free food manufacturer). Dr Schär did not have any input in drafting of this manuscript.

**Conflicts of Interest:** The authors declare no conflict of interest.

#### References

1. Singh, P.; Arora, A.; Strand, T.A.; Leffler, D.A.; Catassi, C.; Green, P.H.; Kelly, C.P.; Ahuja, V.; Makharia, G.K. Global Prevalence of celiac disease: Systematic review and meta-analysis. *Clin. Gastroenterol. Hepatol.* **2018**, *16*, 823–836. [[CrossRef](#)] [[PubMed](#)]
2. Lebowitz, B.; Sanders, D.S.; Green, P.H.R. Coeliac disease. *Lancet* **2018**, *6*, 70–81. [[CrossRef](#)]

3. O'Mahony, S.; Howdle, P.D.; Losowsky, M.S. Review article: Management of patients with non-responsive coeliac disease. *Aliment. Pharmacol. Ther.* **1996**, *10*, 671–680. [[CrossRef](#)] [[PubMed](#)]
4. Baggus, E.M.R.; Hadjivassiliou, M.; Cross, S.; Penny, H.A. How to manage adult coeliac disease: Perspective from the NHS England rare diseases collaborative network for non-responsive and refractory coeliac disease. *Frontline Gastroenterol.* **2019**. [[CrossRef](#)]
5. Mooney, P.D.; Evans, K.E.; Singh, S.; Sanders, D.S. Treatment failure in coeliac disease: A practical guide to investigation and treatment of non-responsive and refractory coeliac disease. *J. Gastrointest. Liver Dis.* **2012**, *21*, 197–203.
6. Caio, G.; Volta, U.; Sapone, A.; Leffler, D.A.; De Giorgio, R.; Catassi, C.; Fasano, A. Celiac disease: A comprehensive current review. *BMC Med.* **2019**, *17*, 142. [[CrossRef](#)] [[PubMed](#)]
7. Dewar, D.H.; Donnelly, S.C.; McLaughlin, S.D.; Johnson, M.W.; Ellis, H.J.; Ciclitira, P.J. Celiac disease: Management of persistent symptoms in patients on a gluten-free diet. *World J. Gastroenterol.* **2012**, *18*, 1348–1356. [[CrossRef](#)]
8. Abdulkarim, A.S.; Burgart, L.J.; See, J.; Murray, J.A. Etiology of nonresponsive celiac disease: Results of a systematic approach. *Am. J. Gastroenterol.* **2002**, *97*, 2016–2021. [[CrossRef](#)]
9. Hadithi, M.; Von Blomberg, B.M.E.; Crusius, J.B.A.; Bloemena, E.; Kostense, P.J.; Meijer, J.W.; Mulder, C.J.; Stehouwer, C.D.; Peña, A.S. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. *Ann. Intern. Med.* **2007**, *147*, 294–302. [[CrossRef](#)]
10. Hill, I.D. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? *Gastroenterology* **2005**, *128*, S25–S32. [[CrossRef](#)]
11. Leffler, D.A.; Schuppan, D. Update on serologic testing in celiac disease. *Am. J. Gastroenterol.* **2010**, *105*, 2520–2524. [[CrossRef](#)] [[PubMed](#)]
12. Ludvigsson, J.F.; Bai, J.C.; Biagi, F.; Card, T.R.; Ciacci, C.; Ciclitira, P.J.; Green, P.H.R.; Hadjivassiliou, M.; Holdoway, A.; A Van Heel, D.; et al. Diagnosis and management of adult coeliac disease: Guidelines from the British Society of Gastroenterology. *Gut* **2014**, *63*, 1210–1228. [[CrossRef](#)] [[PubMed](#)]
13. Aziz, I.; Peerally, M.F.; Barnes, J.H.; Kandasamy, V.; Whiteley, J.C.; Partridge, D.; Vergani, P.; Cross, S.S.; Green, P.H.; Sanders, D.S. The clinical and phenotypical assessment of seronegative villous atrophy; a prospective UK centre experience evaluating 200 adult cases over a 15-year period (2000–2015). *Gut* **2017**, *66*, 1563–1572. [[CrossRef](#)] [[PubMed](#)]
14. Schieppatti, A.; Sanders, D.S.; Biagi, F. Seronegative coeliac disease: Clearing the diagnostic dilemma. *Curr. Opin. Gastroenterol.* **2018**, *34*, 154–158. [[CrossRef](#)]
15. Arguelles-Grande, C.; Tennyson, C.A.; Lewis, S.K.; Green, P.H.; Bhagat, G. Variability in small bowel histopathology reporting between different pathology practice settings: Impact on the diagnosis of coeliac disease. *J. Clin. Pathol.* **2012**, *65*, 242–247. [[CrossRef](#)]
16. Mubarak, A.; Nikkels, P.; Houwen, R.; Kate, F.T. Reproducibility of the histological diagnosis of celiac disease. *Scand. J. Gastroenterol.* **2011**, *46*, 1065–1073. [[CrossRef](#)]
17. Anderson, R.P.; Henry, M.J.; Taylor, R.; Duncan, E.L.; Danoy, P.; Costa, M.J.; Addison, K.; Tye-Din, J.A.; Kotowicz, M.A.; Knight, R.E.; et al. A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways. *BMC Med.* **2013**, *11*, 188. [[CrossRef](#)]
18. Husby, S.; Koletzko, S.; Korponay-Szabó, I.; Mearin, M.; Phillips, A.; Shamir, R.; Troncone, R.; Giersiepen, K.; Branski, D.; Catassi, C.; et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of coeliac disease. *J. Pediatr. Gastroenterol. Nutr.* **2012**, *54*, 136–160. [[CrossRef](#)]
19. Leffler, D.A.; Dennis, M.; Hyett, B.; Kelly, E.; Schuppan, D.; Kelly, C.P. Etiologies and predictors of diagnosis in nonresponsive celiac disease. *Clin. Gastroenterol. Hepatol.* **2007**, *5*, 445–450. [[CrossRef](#)]
20. van Wanrooij, R.L.J.; Bouma, G.; Bontkes, H.J.; Neeffjes-Borst, A.; van Grieken, N.C.; von Blomberg, B.M.E.; Mulder, C.J.J. Outcome of referrals for non-responsive celiac disease in a tertiary center: Low incidence of refractory celiac disease in The Netherlands. *Clin. Transl. Gastroenterol.* **2017**, *8*, e218. [[CrossRef](#)]
21. Oxford, E.C.; Nguyen, D.D.; Sauk, J.; Korzenik, J.; Yajnik, V.; Friedman, S.; Ananthakrishnan, A. Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. *Am. J. Gastroenterol.* **2013**, *108*, 1123–1129. [[CrossRef](#)] [[PubMed](#)]
22. Fine, K.D.; Meyer, R.L.; Lee, E.L. The prevalence and causes of chronic diarrhea in patients with celiac sprue treated with a gluten-free diet. *Gastroenterology* **1997**, *112*, 1830–1838. [[CrossRef](#)] [[PubMed](#)]

23. Barratt, S.M.; Leeds, J.S.; Robinson, K.; Shah, P.; Lobo, A.J.; Mcalindon, M.E.; Sanders, D.S. Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. *Eur. J. Gastroenterol. Hepatol.* **2011**, *23*, 159–165. [[CrossRef](#)] [[PubMed](#)]
24. Bentivoglio, V.P.; Raguseo, L.; Tripaldi, M.; Indrio, F.; Gentile, A.; De Toma, M.; Cristofori, F. Increased prevalence of abdominal pain-functional gastrointestinal disorders in pediatric celiac patients. *Dig. Liver Dis.* **2017**, *49*, e267. [[CrossRef](#)]
25. Testa, A.; Imperatore, N.; Rispo, A.; Rea, M.; Tortora, R.; Nardone, O.M.; Lucci, L.; Accarino, G.; Caporaso, N.; Castiglione, F. Beyond irritable bowel syndrome: The efficacy of the low fodmap diet for improving symptoms in inflammatory bowel diseases and celiac disease. *Dig. Dis.* **2018**, *36*, 271–280. [[CrossRef](#)] [[PubMed](#)]
26. Roncoroni, L.; Bascuñán, K.A.; Doneda, L.; Scricciolo, A.; Lombardo, V.; Branchi, F.; Ferretti, F.; Dell’Osso, B.; Montanari, V.; Bardella, M.T.; et al. A low FODMAP gluten-free diet improves functional gastrointestinal disorders and overall mental health of celiac disease patients: A randomized controlled trial. *Nutrients* **2018**, *10*, 1023. [[CrossRef](#)] [[PubMed](#)]
27. Francavilla, R.; Piccolo, M.; Francavilla, A.; Polimeno, L.; Semeraro, F.; Cristofori, F.; Castellaneta, S.; Barone, M.; Indrio, F.; Gobetti, M.; et al. Clinical and microbiological effect of a multispecies probiotic supplementation in celiac patients with persistent IBS-type symptoms: A randomized, double-blind, placebo-controlled, multicenter trial. *J. Clin. Gastroenterol.* **2019**, *53*, e117–e125. [[CrossRef](#)]
28. Hall, N.J.; Rubin, G.; Charnock, A. Systematic review: Adherence to a gluten-free diet in adult patients with coeliac disease. *Aliment. Pharm. Ther.* **2009**, *30*, 315–330. [[CrossRef](#)]
29. Lerner, B.A.; Phan Vo, L.T.; Yates, S.; Rundle, A.G.; Green, P.H.; Lebowitz, B. Detection of gluten in gluten-free labeled restaurant food: Analysis of crowd-sourced data. *Am. J. Gastroenterol.* **2019**, *114*, 792–797. [[CrossRef](#)]
30. Bottaro, G.; Cataldo, F.; Rotolo, N.; Spina, M.; Corazza, G.R. The clinical pattern of subclinical/silent celiac disease: An analysis on 1026 consecutive cases. *Am. J. Gastroenterol.* **1999**, *94*, 691–696. [[CrossRef](#)]
31. Silvester, J.A.; Kurada, S.; Szwajcer, A.; Kelly, C.P.; Leffler, D.A.; Duerksen, DR. Tests for serum transglutaminase and endomysial antibodies do not detect most patients with celiac disease and persistent villous atrophy on gluten-free diets: A meta-analysis. *Gastroenterology.* **2017**, *153*, 689.e1–701.e1. [[CrossRef](#)] [[PubMed](#)]
32. Pekki, H.; Kurppa, K.; Maki, M.; Huhtala, H.; Sievänen, H.; Laurila, K.; Collin, P.; Kaukinen, K. Predictors and significance of incomplete mucosal recovery in celiac disease after 1 year on a gluten-free diet. *Am. J. Gastroenterol.* **2015**, *110*, 1078–1085. [[CrossRef](#)] [[PubMed](#)]
33. Sharkey, L.M.; Corbett, G.; Currie, E.; Lee, J.; Sweeney, N.; Woodward, J.M. Optimising delivery of care in coeliac disease—Comparison of the benefits of repeat biopsy and serological follow-up. *Aliment. Pharm. Ther.* **2013**, *38*, 1278–1291. [[CrossRef](#)] [[PubMed](#)]
34. Rubio-Tapia, A.; Rahim, M.W.; See, J.A.; Lahr, B.D.; Wu, T.T.; Murray, J.A. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. *Am. J. Gastroenterol.* **2010**, *105*, 1412–1420. [[CrossRef](#)] [[PubMed](#)]
35. Wahab, P.J.; Meijer, J.W.; Mulder, C.J. Histologic follow-up of people with celiac disease on a gluten-free diet: Slow and incomplete recovery. *Am. J. Clin. Pathol.* **2002**, *118*, 459–463. [[CrossRef](#)] [[PubMed](#)]
36. Grefte, J.M.; Bouman, J.G.; Grond, J.; Jansen, W.; Kleibeuker, J.H. Slow and incomplete histological and functional recovery in adult gluten sensitive enteropathy. *J. Clin. Pathol.* **1988**, *41*, 886–891. [[CrossRef](#)] [[PubMed](#)]
37. Costa, A.F.; Sugai, E.; Temprano, M.P.; Niveloni, S.I.; Vázquez, H.G.; Moreno, M.L.; Domínguez-Flores, M.R.; Muñoz-Suano, A.; Smecuol, E.; Stefanolo, J.P.; et al. Gluten immunogenic peptide excretion detects dietary transgressions in treated celiac disease patients. *World J. Gastroenterol.* **2019**, *25*, 1409–1420. [[CrossRef](#)]
38. Moreno, M.L.; Cebolla, A.; Muñoz-Suano, A.; Carrillo-Carrion, C.; Comino, I.; Pizarro, A.; León, F.; Rodríguez-Herrera, A.; Sousa, C. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. *Gut* **2017**, *66*, 250–257. [[CrossRef](#)]
39. Lau, M.S.; Mooney, P.D.; White, W.L.; Rees, M.A.; Wong, S.H.; Kurien, M.; Trott, N.; Leffler, D.A.; Hadjivassiliou, M.; Sanders, D.S. The role of an IgA/IgG-deamidated gliadin peptide point-of-care test in predicting persistent villous atrophy in patients with celiac disease on a gluten-free diet. *Am. J. Gastroenterol.* **2017**, *112*, 1859–1867. [[CrossRef](#)]

40. Hollon, J.R.; Cureton, P.A.; Martin, M.L.; Puppa, E.L.; Fasano, A. Trace gluten contamination may play a role in mucosal and clinical recovery in a subgroup of diet-adherent non-responsive celiac disease patients. *BMC Gastroenterol.* **2013**, *13*, 40. [[CrossRef](#)]
41. Leonard, M.; Cureton, P.; Fasano, A. Indications and use of the gluten contamination elimination diet for patients with nonresponsive celiac disease. *Nutrients* **2017**, *9*, 1129. [[CrossRef](#)] [[PubMed](#)]
42. Olausson, R.W.; Løvik, A.; Tollefsen, S.; Andresen, P.A.; Vatn, M.H.; de Lange, T.; Bratlie, J.; Brandtzaeg, P.; Farstad, I.N.; Lundin, K.E.A. Effect of elemental diet on mucosal immunopathology and clinical symptoms in type 1 refractory celiac disease. *Clin. Gastroenterol. Hepatol.* **2005**, *3*, 875–885. [[CrossRef](#)]
43. Mandal, A.; Mayberry, J. Elemental diet in the treatment of refractory coeliac disease. *Eur. J. Gastroenterol. Hepatol.* **2001**, *13*, 79–80. [[CrossRef](#)] [[PubMed](#)]
44. Ludvigsson, J.F.; Leffler, D.A.; Bai, J.C.; Hadjivassiliou, M.; Kaukinen, K.; Kelly, C.P.; Leonard, J.N.; Lundin, K.E.A.; Murray, J.A.; Sanders, D.S.; et al. The Oslo definitions for coeliac disease and related terms. *Gut* **2013**, *62*, 43–52. [[CrossRef](#)]
45. Rubio-Tapia, A.; Kelly, D.G.; Lahr, B.D.; Dogan, A.; Wu, T.T.; Murray, J.A. Clinical staging and survival in refractory celiac disease: A single center experience. *Gastroenterology* **2009**, *136*, 99–107. [[CrossRef](#)] [[PubMed](#)]
46. Malamut, G.; Afchain, P.; Verkarre, V.; Lecomte, T.; Amiot, A.; Damotte, D.; Bouhnik, Y.; Colombel, J.-F.; Delchier, J.-C.; Allez, M.; et al. Presentation and long-term follow-up of refractory celiac disease: Comparison of type I with type II. *Gastroenterology* **2009**, *136*, 81–90. [[CrossRef](#)]
47. Roshan, B.; Leffler, D.A.; Jamma, S.; Dennis, M.D.; Sheth, S.; Falchuk, K.R.; Najarian, R.M.; Goldsmith, J.; Tariq, S.; Schuppan, D.; et al. The incidence and clinical spectrum of refractory celiac disease in a north american referral center. *Am. J. Gastroenterol.* **2011**, *106*, 923–928. [[CrossRef](#)]
48. Rowinski, S.A.; Christensen, E. Epidemiologic and therapeutic aspects of refractory coeliac disease—A systematic review. *Dan. Med. J.* **2016**, *63*, A5307.
49. Cellier, C.; Delabesse, E.; Helmer, C.; Mende, S.; Seegebarth, A.; Siegmund, B.; Hennig, S.; Todorova, K.; Rosenwald, A.; Daum, S.; et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. *Lancet* **2000**, *356*, 203–208. [[CrossRef](#)]
50. Al-Toma, A.; Verbeek, W.H.; Mulder, C.J. Update on the management of refractory coeliac disease. *J. Gastrointestin. Liver Dis.* **2007**, *16*, 57–63.
51. Al-Toma, A.; Verbeek, W.H.; Hadithi, M.; von Blomberg, B.M.; Mulder, C.J. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: Retrospective evaluation of single-centre experience. *Gut* **2007**, *56*, 1373–1378. [[CrossRef](#)] [[PubMed](#)]
52. Daum, S.; Ipczynski, R.; Schumann, M.; Wahnschaffe, U.; Zeitz, M.; Ullrich, R. High rates of complications and substantial mortality in both types of refractory sprue. *Eur. J. Gastroenterol. Hepatol.* **2009**, *21*, 66–70. [[CrossRef](#)] [[PubMed](#)]
53. Cellier, C.; Patey, N.; Mauvieux, L.; Jabri, B.; Delabesse, E.; Cervoni, J.-P.; Burtin, M.-L.; Guy-Grand, D.; Bouhnik, Y.; Modigliani, R.; et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. *Gastroenterology* **1998**, *114*, 471–481. [[CrossRef](#)]
54. Etersperger, J.; Montcuquet, N.; Malamut, G.; Guegan, N.; Lopez-Lastra, S.; Gayraud, S.; Reimann, C.; Vidal, E.; Cagnard, N.; Villarese, P.; et al. Interleukin-15-dependent T-cell-like innate intraepithelial lymphocytes develop in the intestine and transform into lymphomas in celiac disease. *Immunity* **2016**, *45*, 610–625. [[CrossRef](#)]
55. Bagdi, E.; Diss, T.C.; Munson, P.; Isaacson, P.G. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. *Blood* **1999**, *94*, 260–264. [[CrossRef](#)]
56. Liu, H.; Brais, R.; Lavergne-Slove, A.; Jeng, Q.; Payne, K.; Ye, H.; Liu, Z.; Carreras, J.; Huang, Y.; Bacon, C.M.; et al. Continual monitoring of intraepithelial lymphocyte immunophenotype and clonality is more important than snapshot analysis in the surveillance of refractory coeliac disease. *Gut* **2010**, *59*, 452–460. [[CrossRef](#)]
57. Celli, R.; Hui, P.; Triscott, H.; Bogardus, S.; Gibson, J.; Hwang, M.; Robert, M.E. Clinical insignificance of monoclonal T-cell populations and duodenal intraepithelial T-cell phenotypes in celiac and nonceliac patients. *Am. J. Surg. Pathol.* **2019**, *43*, 151–160. [[CrossRef](#)]
58. Verbeek, W.H.; Goerres, M.S.; von Blomberg, B.M.; Oudejans, J.J.; Scholten, P.E.; Hadithi, M.; Al-Toma, A.; Schreurs, M.W.; Mulder, C.J. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts

- T-cell lymphoma development more accurately than T-cell clonality analysis in refractory celiac disease. *Clin. Immunol.* **2008**, *126*, 48–56. [[CrossRef](#)]
59. Leon, F. Flow cytometry of intestinal intraepithelial lymphocytes in celiac disease. *J. Immunol. Methods* **2011**, *363*, 177–186. [[CrossRef](#)]
60. Woodward, J. Improving outcomes of refractory celiac disease—Current and emerging treatment strategies. *Clin. Exp. Gastroenterol.* **2016**, *9*, 225–236. [[CrossRef](#)]
61. Cheminant, M.; Bruneau, J.; Malamut, G.; Sibon, D.; Guegan, N.; van Gils, T.; Cording, S.; Trinquand, A.; Verkarre, V.; Lhermitte, L.; et al. NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: A CELAC study. *Gut* **2019**, *68*, 1396–1405. [[CrossRef](#)] [[PubMed](#)]
62. Snowden, J.A.; O’Connell, S.; Hawkins, J.; Dalley, C.; Jack, A.; Mannari, D.; McNamara, C.; Scott, M.; Shenton, G.; Soilleux, E.; et al. Haematological cancers: Improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS). *J. Clin. Pathol.* **2017**, *70*, 461–468. [[CrossRef](#)] [[PubMed](#)]
63. Rubio-Tapia, A.; Murray, J.A. Classification and management of refractory coeliac disease. *Gut* **2010**, *59*, 547–557. [[CrossRef](#)] [[PubMed](#)]
64. Brar, P.; Lee, S.; Lewis, S.; Egbuna, I.; Bhagat, G.; Green, P.H. Budesonide in the treatment of refractory celiac disease. *Am. J. Gastroenterol.* **2007**, *102*, 2265–2269. [[CrossRef](#)]
65. Edsbacker, S.; Larsson, P.; Wollmer, P. Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules. *Eur. J. Gastroenterol. Hepatol.* **2002**, *14*, 1357–1362. [[CrossRef](#)]
66. Mukewar, S.S.; Sharma, A.; Rubio-Tapia, A.; Wu, T.T.; Jabri, B.; Murray, J.A. Open-capsule budesonide for refractory celiac disease. *Am. J. Gastroenterol.* **2017**, *112*, 959–967. [[CrossRef](#)]
67. Goerres, M.S.; Meijer, J.W.; Wahab, P.J.; Kerckhaert, J.A.; Groenen, P.J.; Van Krieken, J.H.; Mulder, C.J. Azathioprine and prednisone combination therapy in refractory coeliac disease. *Aliment. Pharmacol. Ther.* **2003**, *18*, 487–494. [[CrossRef](#)]
68. Tack, G.J.; van Asseldonk, D.P.; van Wanrooij, R.L.; van Bodegraven, A.A.; Mulder, C.J. Tioguanine in the treatment of refractory coeliac disease—A single centre experience. *Aliment. Pharmacol. Ther.* **2012**, *36*, 274–281. [[CrossRef](#)]
69. Costantino, G.; della Torre, A.; Lo Presti, M.A.; Caruso, R.; Mazzon, E.; Fries, W. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. *Dig. Liver Dis.* **2008**, *40*, 74. [[CrossRef](#)]
70. Gillett, H.R.; Arnott, I.D.; McIntyre, M.; Campbell, S.; Dahele, A.; Priest, M.; Jackson, R.; Ghosh, S. Successful infliximab treatment for steroid-refractory celiac disease: A case report. *Gastroenterology* **2002**, *122*, 800–805. [[CrossRef](#)]
71. Jamma, S.; Leffler, D.A.; Dennis, M.; Najarian, R.M.; Schuppan, D.B.; Sheth, S.; Kelly, C.P. Small intestinal release mesalamine for the treatment of refractory celiac disease type I. *J. Clin. Gastroenterol.* **2011**, *45*, 30–33. [[CrossRef](#)] [[PubMed](#)]
72. Collin, P.; Rondonotti, E.; Lundin, K.E.; Spada, C.; Keuchel, M.; Kaukinen, K.; de Franchis, R.; Jacobs, M.A.; Villa, F.; Mulder, C.J. Video capsule endoscopy in celiac disease: Current clinical practice. *J. Dig. Dis.* **2012**, *13*, 94–99. [[CrossRef](#)] [[PubMed](#)]
73. Hadithi, M.; Mallant, M.; Oudejans, J.; van Waesberghe, J.H.; Mulder, C.J.; Comans, E.F. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. *J. Nucl. Med.* **2006**, *47*, 1622–1627. [[PubMed](#)]
74. Van Weyenberg, S.J.; Meijerink, M.R.; Jacobs, M.A.; van Kuijk, C.; Mulder, C.J.; van Waesberghe, J.H. MR enteroclysis in refractory celiac disease: Proposal and validation of a severity scoring system. *Radiology* **2011**, *259*, 151–161. [[CrossRef](#)] [[PubMed](#)]
75. Al-Bawardy, B.; Barlow, J.M.; Vasconcelos, R.N.; Kim, S.T.; Bruining, D.H.; Hansel, S.L.; Sheedy, S.P.; Murray, J.A.; Rubio-Tapia, A.; Rajan, E.; et al. Cross-sectional imaging in refractory celiac disease. *Abdom. Radiol. (NY)* **2017**, *42*, 389–395. [[CrossRef](#)]
76. Hadithi, M.; Al-toma, A.; Oudejans, J.; van Bodegraven, A.A.; Mulder, C.J.; Jacobs, M. The Value of double-balloon enteroscopy in patients with refractory coeliac disease. *Am. J. Gastroenterol.* **2007**, *102*, 987–996. [[CrossRef](#)]

77. Mallant, M.; Hadithi, M.; Al-toma, A.; Kater, M.; Jacobs, M.; Manoliu, R.; Mulder, C.; van Waesberghe, J.H. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. *World J. Gastroenterol.* **2007**, *13*, 1696–1700. [[CrossRef](#)]
78. Daum, S.; Wahnschaffe, U.; Glasenapp, R.; Borchert, M.; Ullrich, R.; Zeitz, M.; Faiss, S. Capsule endoscopy in refractory celiac disease. *Endoscopy* **2007**, *39*, 455–458. [[CrossRef](#)]
79. Tack, G.J.; Verbeek, W.H.; Al-Toma, A.; Kuik, D.J.; Schreurs, M.W.J.; Visser, O.; Mulder, C.J.J. Evaluation of cladribine treatment in refractory celiac disease type II. *World J. Gastroenterol.* **2011**, *17*, 506–513. [[CrossRef](#)]
80. Al-Toma, A.; Goerres, M.S.; Meijer, J.W.; von Blomberg, B.M.; Wahab, P.J.; Kerckhaert, J.A.; Mulder, C.J. Cladribine therapy in refractory celiac disease with aberrant T cells. *Clin. Gastroenterol. Hepatol.* **2006**, *4*, 1322–1327. [[CrossRef](#)]
81. Schmidt, C.; Kasim, E.; Schlake, W.; Gerken, G.; Giese, T.; Stallmach, A. TNF-alpha antibody treatment in refractory collagenous sprue: Report of a case and review of the literature. *Z. Gastroenterol.* **2009**, *47*, 575–578. [[CrossRef](#)] [[PubMed](#)]
82. Vivas, S.; Ruiz de Morales, J.M.; Ramos, F.; Suarez-Vilela, D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. *N. Engl. J. Med.* **2006**, *354*, 2514–2515. [[CrossRef](#)] [[PubMed](#)]
83. Wahab, P.J.; Crusius, J.B.; Meijer, J.W.; Uil, J.J.; Mulder, C.J. Cyclosporin in the treatment of adults with refractory coeliac disease—An open pilot study. *Aliment. Pharmacol. Ther.* **2000**, *14*, 767–774. [[CrossRef](#)] [[PubMed](#)]
84. Mulder, C.J.; Wahab, P.J.; Meijer, J.W.; Metselaar, E. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. *Eur. J. Gastroenterol. Hepatol.* **2001**, *13*, 1183–1188. [[CrossRef](#)] [[PubMed](#)]
85. Cellier, C.; Bouma, G.; van Gils, T.; Khater, S.; Malamut, G.; Crespo, L.; Collin, P.; Green, P.H.R.; Crowe, S.E.; Tsuji, W.; et al. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: A phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. *Lancet Gastroenterol. Hepatol.* **2019**, *4*, 960–970. [[CrossRef](#)]
86. Snowden, J.A.; Badoglio, M.; Labopin, M.; Giebel, S.; McGrath, E.; Marjanovic, Z.; Burman, J.; Moore, J.; Rovira, M.; Wulffraat, N.M.; et al. Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune disease. *Blood Adv.* **2017**, *1*, 2742–2755. [[CrossRef](#)] [[PubMed](#)]
87. Snowden, J.A.; Badoglio, M.; Tobias Alexander, T. The rise of autologous HCT for autoimmune diseases: What is behind it and what does it mean for the future of treatment? An update on behalf of the EBMT Autoimmune Diseases Working Party. *Expert Rev. Clin. Immunol.* **2019**. [[CrossRef](#)]
88. Duarte, R.F.; Labopin, M.; Bader, P.; Basak, G.W.; Bonini, C.; Chabannon, C.; Corbacioglu, S.; Dreger, P.; Dufour, C.; Gennery, A.R.; et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2019. *Bone Marrow Transplant.* **2019**, *54*, 1525–1552. [[CrossRef](#)]
89. Al-Toma, A.; Visser, O.J.; van Roessel, H.M.; von Blomberg, B.M.; Verbeek, W.H.; Scholten, P.E.; Ossenkuppele, G.J.; Huijgens, P.C.; Mulder, C.J. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. *Blood* **2007**, *109*, 2243–2249. [[CrossRef](#)]
90. Al-Toma, A.; Verbeek, W.H.; Visser, O.J.; Kuijpers, K.C.; Oudejans, J.J.; Kluin-Nelemans, H.C.; Mulder, C.J.; Huijgens, P.C. Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. *Dig. Liver Dis.* **2007**, *39*, 634–641. [[CrossRef](#)]
91. Nijeboer, P.; van Wanrooij, R.L.J.; van Gils, T.; Wierdsma, N.J.; Tack, G.J.; Witte, B.I.; Bontkes, H.J.; Visser, O.; Mulder, C.; Bouma, G. Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor. *United Eur. Gastroenterol. J.* **2017**, *5*, 208–217. [[CrossRef](#)] [[PubMed](#)]
92. Van Beurden, Y.H.; van Gils, T.; van Gils, N.A.; Kassam, Z.; Mulder, C.J.; Aparicio-Pages, N. Serendipity in refractory celiac disease: Full recovery of duodenal villi and clinical symptoms after fecal microbiota transfer. *J. Gastrointestin. Liver Dis.* **2016**, *25*, 385–388. [[PubMed](#)]
93. Girbovan, A.; Sur, G.; Samasca, G.; Lupan, I. Dysbiosis a risk factor for celiac disease. *Med. Microbiol. Immunol.* **2017**, *206*, 83–91. [[CrossRef](#)] [[PubMed](#)]
94. Stepankova, R.; Tlaskalova-Hogenova, H.; Sinkora, J.; Jodl, J.; Fric, P. Changes in jejunal mucosa after long-term feeding of germfree rats with gluten. *Scand. J. Gastroenterol.* **1996**, *31*, 551–557. [[CrossRef](#)] [[PubMed](#)]

95. Sanchez, E.; Donat, E.; Ribes-Koninckx, C.; Fernandez-Murga, M.L.; Sanz, Y. Duodenal-mucosal bacteria associated with celiac disease in children. *Appl. Environ. Microbiol.* **2013**, *79*, 5472–5479. [[CrossRef](#)] [[PubMed](#)]
96. Hansen, C.H.; Holm, T.L.; Krych, L.; Andresen, L.; Nielsen, D.S.; Rune, I.; Hansen, A.K.; Skov, S. Gut microbiota regulates NKG2D ligand expression on intestinal epithelial cells. *Eur. J. Immunol.* **2013**, *43*, 447–457. [[CrossRef](#)] [[PubMed](#)]
97. Collado, M.C.; Donat, E.; Ribes-Koninckx, C.; Calabuig, M.; Sanz, Y. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. *J. Clin. Pathol.* **2009**, *62*, 264–269. [[CrossRef](#)]
98. Schippa, S.; Iebba, V.; Barbato, M.; Di Nardo, G.; Totino, V.; Checchi, M.P.; Longhi, C.; Maiella, G.; Cucchiara, S.; Conte, M.P. A distinctive ‘microbial signature’ in celiac pediatric patients. *BMC Microbiol.* **2010**, *10*, 175. [[CrossRef](#)]
99. Galipeau, H.J.; Verdu, E.F. Gut microbes and adverse food reactions: Focus on gluten related disorders. *Gut Microbes* **2014**, *5*, 594–605. [[CrossRef](#)]
100. Wacklin, P.; Kaukinen, K.; Tuovinen, E.; Collin, P.; Lindfors, K.; Partanen, J.; Mäki, M.; Mättö, J. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. *Inflamm. Bowel. Dis.* **2013**, *19*, 934–941. [[CrossRef](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).